In the previous anti-tumor targeted therapy, 83.6% and 76.0% of the patients in the fruquintinib group and regorafenib group received anti-VEGF therapy, and 25.5% and 20.0% of the patients received anti-EGFR therapy. Here, EGFR is linked to neoplasm.